Medtronic Launches Next-Gen Pipeline™ Vantage with Shield Technology™ in China, Marking a New Milestone in Minimally Invasive Aneurysm Treatment

Source: Medical Device Business Review, Chao News Client

On September 26, at the 4th Global Digital Trade Expo(hereinafter referred to as "Data Trade Fair")Above, Medtronic has launched its newly approved fourth-generation Pipeline™ Vantage with Shield Technology™ surface-modified flow-diverting stent.(hereinafter referred to as "Pipeline™ Vantage")Debut,This is also the first public display of the product after its approval.

Source: Chao News Client

The launch of Pipeline™ Vantage not only marks a new phase in the treatment of brain aneurysms that is more minimally invasive and safer, but also provides Chinese patients with more diverse and higher-quality treatment options.

Data shows that the Pipeline™ Embolization Device product was initially part of Medtronic in 2015.Acquired for $43 billion when Medtronic purchased Covidien, currentlyIt is a popular product in the field of flow diversion and also the most extensively researched flow-diverting stent globally.This therapy has been introduced to the Chinese market for ten years.Now it has been updated to the fourth.So far, globally, more than 250,000 patients and over 40,000 patients in China with cerebral aneurysms have benefited from this.

The core breakthrough of the upgraded Pipeline™ Vantage stent, which is being exhibited for the first time, is the coating of phosphorylcholine polymer on the surface of the stent wires, which are finer than a hair.This biomaterial is one of the components of human red blood cells. It acts like an "invisible cloak" for the stent, allowing the stent to be implanted into the cerebral blood vessel where the aneurysm is located without being recognized by the body as a "foreign object" and attacked. This reduces the formation of blood clots and lowers the incidence of complications. At the same time,The new generation product can be delivered using finer microcatheters, akin to being equipped with more flexible "tools." Even blood vessels as small as 2 millimeters in diameter can be navigated smoothly, further enhancing the accessibility of innovative therapies.¹

Against the backdrop of an aging population, the prevalence of aneurysm diseases is also increasing year by year."Craniotomy clipping" and "transcatheter aneurysm coil embolization" are the two traditional treatment methods for aneurysms. However, with the rapid development of neurointerventional materials and techniques, the treatment of cerebrovascular conditions has now entered the era of minimally invasive interventions.A New Approach to Treating Aneurysms —— The Emergence of Flow Diverter Implantation。

This therapy achieves its treatment purpose by implanting a dense mesh stent to remodel the blood flow direction within cerebral vessels, causing the aneurysm to gradually close. A spokesperson for Medtronic explained with a vivid metaphor: "If we compare blood vessels to 'roads,' traditional embolization therapies of the past were like filling 'potholes' on the road surface—wherever there was a 'hole,' it was filled, which is only a temporary solution."The core of flow diversion therapy is to change the direction of blood flow, akin to 'paving' within the blood vessels, addressing the root cause.”¹

According to Huang Xiaosong, Director of the Department of Neurology III at Hunan Provincial Second People's Hospital (Provincial Brain Hospital),The dense mesh stent is made by weaving dozens of microscopic metal wires. Due to its very tight weave and extremely fine mesh, it has excellent flexibility and adheres to the vessel wall of large aneurysms, making it difficult for blood flow to enter the aneurysm. It has a strong flow-diverting effect and can reduce the risk of intraoperative rupture and bleeding.

Mr. Xiao Kejin, Director of the Neurology Department of Yueyang Traditional Chinese Medicine Hospital, said that the blood flow导向密网支架植入术 isThe Most Cutting-Edge Technology in the Field of Cerebrovascular Treatment Currently，Through the revolutionary "vascular reconstruction" concept, using high-density braided stents, the blood flow velocity within the aneurysm is reduced by more than 95%., fundamentally blocking the blood supply to the tumor and promoting natural repair of the vascular endothelium. The cure rate of this technology is 40% higher than traditional methods, with a recurrence rate reduced to less than 3%.

Notably, four days ago (September 24, 2025),Medtronic Announces Appointment of Adam S. Arthur, M.D.Neurovascular BusinessThe Chief Medical Officer (CMO) appointment will officially take effect on September 30, 2025. This marks another personnel adjustment following the replacement of the division's president in May of last year.

Medtronic 2025 Fiscal Year Report

In response, Medtronic is also actively promoting the construction of a digital ecosystem for flow diversion therapy in China. Through its digital therapy promotion program, it combines AI digital human guides, online therapy promotion to enhance understanding, and virtual simulators for zero-risk refinement of operational skills, helping doctors shorten the learning curve, enabling innovative therapies to truly enter clinical practice, and driving the overall development of flow diversion therapy in China.

This product innovation, coupled with the appointment of a new leader, may help Medtronic boost its neurovascular performance.

References:

Source of Note 1: Chaonews Client: "‘Old Friend’ Brings New Breakthroughs – Medtronic's New Product Debuts at the Digital Trade Fair"

Subscription Account of Yudu County People's Hospital: "The 'Black Technology' for Safe Treatment of Intracranial Aneurysms — New Flow Diverter Dense Mesh Stent"